한글목차

메타보트로픽 글루타민산 수용체의 동향과 예측

세계의 메타보트로픽 글루타민산 수용체 시장 규모는 2024-2030년 CAGR 11.0%로 성장하며, 2030년까지 추정 23억 달러에 달할 것으로 예측되고 있습니다. 이 시장의 주요 촉진요인은 신경질환의 유병률 증가, 가처분소득의 증가, 세계의 고령자 인구의 증가입니다. 세계의 메타보트로픽 글루타민산 수용체 시장의 미래는 주의력결핍 과잉행동장애(ADHD), 알츠하이머병, 만성폐쇄성폐질환(COPD) 시장의 기회로 유망시되고 있습니다.

메타보트로픽 글루타민산 수용체 시장 인사이트

Lucintel은 mGlur5가 예측 기간 중 가장 높은 성장을 달성할 것으로 예측하고 있습니다.

북미는 확립된 헬스케어 인프라의 존재, 연구 자금의 증가, 이 지역의 신경질환을 앓는 방대한 환자 수에 의해 예측 기간 중 가장 높은 성장이 전망됩니다.

자주 묻는 질문

Q.1 메타보트로픽 글루타민산 수용체 시장 규모는?

A1.세계의 메타보트로픽 글루타민산 수용체 시장은 2030년까지 추정 23억 달러에 달할 것으로 예상되고 있습니다.

Q.2 메타보트로픽 글루타민산 수용체 시장의 성장 예측은?

A2.세계의 메타보트로픽 글루타민산 수용체 시장은 2024-2030년 CAGR 11.0%로 성장할 것으로 예상되고 있습니다.

Q.3 메타보트로픽 글루타민산 수용체 시장의 성장에 영향을 미치는 주요 촉진요인은 무엇인가?

A3.이 시장의 주요 촉진요인은 신경질환의 유병률 증가, 가처분소득의 증가, 세계의 고령자 인구의 증가입니다.

Q4.시장의 주요 부문은?

A4.주의력결핍 과잉행동장애(ADHD), 알츠하이머병, 만성폐쇄성폐질환(COPD) 시장의 기회에 의해 세계의 메타보트로픽 글루타민산 수용체 시장의 미래는 유망하다고 생각됩니다.

Q5.시장의 주요 기업은?

A5.주요 메타보트로픽 글루타민산 수용체 기업은 다음과 같습니다.

• Eli Lilly and Company
• Novartis International
• Prexton Therapeutics
• Addex Therapeutics
• Taisho Pharmaceutical Holding
• Astrazeneca
• Domain Therapeutic
• Abcam
• Johnson & Johnson
• Medgenic

Q6.향후 최대가 되는 시장 부문은?

A6.Lucintel은 mGlur5가 예측 기간 중 가장 높은 성장을 달성할 것으로 예측하고 있습니다.

Q7.시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은?

A7.북미는 확립된 헬스케어 인프라의 존재, 연구 자금의 증가, 이 지역의 신경질환으로 이환하는 방대한 환자 수로 인해 예측 기간 중 가장 높은 성장을 나타낼 것으로 예상됩니다.

Q8.리포트의 커스터마이즈는 가능?

A8.네, Lucintel은 추가 비용 없이 10%의 커스터마이즈를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 메타보트로픽 글루타민산 수용체 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석 : 2018-2030년

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 메타보트로픽 글루타민산 수용체 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 메타보트로픽 글루타민산 수용체 시장 : 제품 유형별
  • mGluR2
  • mGluR4
  • mGluR5
• 세계의 메타보트로픽 글루타민산 수용체 시장 : 용도별
  • 주의력결핍 과잉행동장애(ADHD)
  • 알츠하이머병
  • 만성폐쇄성폐질환(COPD)

제4장 시장 동향과 예측 분석 : 지역별(2018-2030년)

• 세계의 메타보트로픽 글루타민산 수용체 시장 : 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 경쟁의 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 제품 유형별
  • 용도별
  • 지역별
• 세계의 메타보트로픽 글루타민산 수용체 시장에서 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 메타보트로픽 글루타민산 수용체 시장의 능력 확대
  • 세계의 메타보트로픽 글루타민산 수용체 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Eli Lilly and Company
• Novartis International
• Prexton Therapeutics
• Addex Therapeutics
• Taisho Pharmaceutical Holding
• Astrazeneca
• Domain Therapeutic
• Abcam
• Johnson & Johnson
• Medgenic

영문목차

Metabotropic Glutamate Receptor Trends and Forecast

The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets. The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

A more than 150-page report is developed to help in your business decisions.

Metabotropic Glutamate Receptor by Segment

The study includes a forecast for the global metabotropic glutamate receptor by product type, application, and region.

Metabotropic Glutamate Receptor Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• mGluR2
• mGluR4
• mGluR5

Metabotropic Glutamate Receptor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Attention Deficit Hyperactivity Disorder
• Alzheimer's Disease
• Chronic Obstructive Pulmonary Disease

Metabotropic Glutamate Receptor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• Europe
• Asia Pacific
• ROW

List of Metabotropic Glutamate Receptor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metabotropic glutamate receptor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metabotropic glutamate receptor companies profiled in this report include-

• Eli Lilly and Company
• Novartis International
• Prexton Therapeutics
• Addex Therapeutics
• Taisho Pharmaceutical Holding
• Astrazeneca
• Domain Therapeutic
• Abcam
• Johnson & Johnson
• Medgenic

Metabotropic Glutamate Receptor Market Insights

Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Features of the Global Metabotropic Glutamate Receptor Market

Market Size Estimates: Metabotropic glutamate receptor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metabotropic glutamate receptor market size by product type, application, and region in terms of value ($B).

Regional Analysis: Metabotropic glutamate receptor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, application, and regions for the metabotropic glutamate receptor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metabotropic glutamate receptor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the metabotropic glutamate receptor market size?

Answer: The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030.

Q.2 What is the growth forecast for metabotropic glutamate receptor market?

Answer: The global metabotropic glutamate receptor market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the metabotropic glutamate receptor market?

Answer: The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

Q4. What are the major segments for metabotropic glutamate receptor market?

Answer: The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets.

Q5. Who are the key metabotropic glutamate receptor market companies?

Answer: Some of the key metabotropic glutamate receptor companies are as follows.

• Eli Lilly and Company
• Novartis International
• Prexton Therapeutics
• Addex Therapeutics
• Taisho Pharmaceutical Holding
• Astrazeneca
• Domain Therapeutic
• Abcam
• Johnson & Johnson
• Medgenic

Q6. Which metabotropic glutamate receptor market segment will be the largest in future?

Answer: Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

Q7. In metabotropic glutamate receptor market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the metabotropic glutamate receptor market by product type (mGlur2, mGlur4, and mGlur5), application (attention deficit hyperactivity disorder, alzheimer's disease, and chronic obstructive pulmonary disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metabotropic Glutamate Receptor Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Metabotropic Glutamate Receptor Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Metabotropic Glutamate Receptor Market by Product Type
  • 3.3.1: mGluR2
  • 3.3.2: mGluR4
  • 3.3.3: mGluR5
• 3.4: Global Metabotropic Glutamate Receptor Market by Application
  • 3.4.1: Attention Deficit Hyperactivity Disorder (ADHD)
  • 3.4.2: Alzheimer's Disease
  • 3.4.3: Chronic Obstructive Pulmonary Disease (COPD)

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Metabotropic Glutamate Receptor Market by Region
• 4.2: North American Metabotropic Glutamate Receptor Market
  • 4.2.2: North American Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
• 4.3: European Metabotropic Glutamate Receptor Market
  • 4.3.1: European Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
  • 4.3.2: European Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
• 4.4: APAC Metabotropic Glutamate Receptor Market
  • 4.4.1: APAC Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
  • 4.4.2: APAC Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
• 4.5: ROW Metabotropic Glutamate Receptor Market
  • 4.5.1: ROW Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
  • 4.5.2: ROW Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease,and Chronic Obstructive Pulmonary Disease

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Application
  • 6.1.3: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Region
• 6.2: Emerging Trends in the Global Metabotropic Glutamate Receptor Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Metabotropic Glutamate Receptor Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metabotropic Glutamate Receptor Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Eli Lilly and Company
• 7.2: Novartis International
• 7.3: Prexton Therapeutics
• 7.4: Addex Therapeutics
• 7.5: Taisho Pharmaceutical Holding
• 7.6: Astrazeneca
• 7.7: Domain Therapeutic
• 7.8: Abcam
• 7.9: Johnson & Johnson
• 7.10: Medgenic